BSc · MBBS · PGDip (Oncology) · MRCP · FRCR · MD
Clinical Lead for Brachytherapy at Mount Vernon Cancer Centre.
Urological and gynaecological oncology, and complex interstitial brachytherapy
including gynaecological, breast and soft tissue indications.
Systemic therapies — radical and palliative.
Dr Mohammed Abdul-latif is a Consultant Clinical Oncologist whose practice centres on urological and gynaecological cancers alongside complex brachytherapy. At Mount Vernon Cancer Centre he holds the post of Clinical Lead for brachytherapy, overseeing and delivering advanced treatment across a broad range of tumour sites.
Brachytherapy places a radiation source directly within or immediately adjacent to a tumour, allowing a very high dose to be delivered to the target while sparing surrounding healthy tissue in a way that external beam radiotherapy cannot match. Complex brachytherapy takes this further: rather than relying on standard applicators alone, it involves the image-guided placement of interstitial needles and catheters into the tumour itself, with the implant designed around each patient's individual anatomy and disease.
Dr Abdul-latif undertakes complex delivery for gynaecological, urological, oesophageal and rectal cancers, including contact radiotherapy, and performs interstitial implants for rarer presentations involving the skin, breast and soft tissues. Techniques of this kind remain available in only a small number of UK centres, and they are frequently what makes curative treatment possible where surgery would otherwise be the only option, or where no option remained at all.
He established a dedicated breast brachytherapy programme at Mount Vernon. Its most valuable application is in women whose breast cancer has recurred after previous radiotherapy, where standard practice has long been mastectomy, as the breast cannot usually be treated a second time with external beam radiotherapy. Multicatheter interstitial brachytherapy allows a second course of radiotherapy to be delivered to the tumour bed alone, with a steep dose fall-off that protects the previously irradiated skin, lung and heart.
For carefully selected patients this makes breast conservation a realistic alternative to mastectomy in the salvage setting. The programme also supports accelerated partial breast irradiation and palliative indications, and he has published on interstitial breast brachytherapy dosimetry.
His wider radiotherapy practice includes modern external beam techniques such as VMAT/IMRT and stereotactic radiotherapy (SBRT/SABR), and hydrogel spacer (SpaceOAR) implantation forms a routine part of his prostate cancer treatment protocols. He also maintains an active interest in systemic treatment, managing patients receiving chemotherapy, targeted therapies and immunotherapy across a variety of clinical settings.
Dr Abdul-latif qualified from Imperial College School of Medicine in 2013, finishing in the top decile of his year, and trained across North London hospitals in general medicine before specialising in clinical oncology. He holds a Postgraduate Diploma (PGDip) in Oncology and a Doctorate of Medicine (MD) from the University of Manchester, completed under the supervision of Professor Peter Hoskin, with a thesis on the role of functional MRI in cervical cancer. He publishes regularly and presents at international meetings including ESTRO. He was awarded the Royal College of Radiologists' Kay-Durrant Fellowship, which took him to France and Italy for further training in breast, rectal and head and neck brachytherapy.
He is an Honorary Senior Lecturer at Brunel Medical School, a role that recognises a substantial ongoing contribution to university teaching alongside clinical practice. It involves the delivery and design of undergraduate oncology teaching, supervision and assessment of medical students during their clinical placements, examining, and the supervision of student research projects, as well as supporting the school's wider academic and curriculum development.
He speaks English and Arabic. He is recognised by all major private health insurers, including as a Bupa Platinum, Fee Assured consultant. He also holds an Education Fellowship at the Institute of Cancer Research and is Module Lead for Oncology for Brunel Medical School students at Mount Vernon Cancer Centre.
Dr Abdul-Latif's practice combines a broad oncological remit with specific technical expertise in brachytherapy — from routine intracavitary treatments through to complex interstitial implants, salvage re-irradiation and organ-preserving approaches.
Signature Practice
Image-guided interstitial needle and catheter implants designed around each patient's anatomy, for gynaecological, urological, oesophageal, rectal, skin, soft tissue and breast disease — including salvage and re-irradiation approaches for patients where standard options have been exhausted.
Clinical Lead at Mount Vernon Cancer Centre. Trained in gynaecological, urological, rectal, oesophageal, breast, skin and soft tissue brachytherapy — including salvage and re-irradiation, and organ-preservation approaches.
View the brachytherapy service →Management of prostate, bladder, cervical, endometrial, vaginal and vulval cancers, including chemoradiotherapy and concurrent systemic treatments, delivered with both radical and palliative intent.
IMRT, VMAT, and stereotactic ablative radiotherapy (SABR/SBRT). SpaceOAR hydrogel spacer insertion for prostate cancer. Image-guided radiotherapy (IGRT) and MRI-guided adaptive planning.
Chemotherapy, immunotherapy and targeted therapies across gynaecological and urological malignancies — in both curative and palliative settings, including concurrent chemoradiotherapy.
Management of pelvic radiation disease in both the acute and chronic phase — a clinically important area for patients who have undergone pelvic radiotherapy, and a specific research and clinical interest.
Regular first-author presenter at ESTRO; published in Clinical Oncology, Brachytherapy, BMJ Open, BMJ Oncology, and Cancer Treatment Reviews. Education fellow at the Institute of Cancer Research.
Salvage and re-irradiation brachytherapy — including breast-conserving approaches to avoid mastectomy, and rectal-preserving approaches to avoid a stoma — is an area requiring highly specialised training and experience, and represents an alternative for patients where standard options have been exhausted. Read more →
A full range of radiotherapy, brachytherapy and systemic treatment services, across urological and gynaecological malignancies and beyond. All modalities are offered with both radical and palliative intent as appropriate.
Full brachytherapy service →
Intracavitary and interstitial brachytherapy for cervical, endometrial, vaginal and vulval cancers. MRI-guided adaptive planning. Includes salvage and re-irradiation brachytherapy for recurrent gynaecological malignancy.
Read more →High-dose-rate (HDR) prostate brachytherapy as monotherapy or boost, and permanent seed implant (LDR). SpaceOAR hydrogel spacer insertion to protect the rectum. Includes focal salvage HDR brachytherapy for locally relapsed prostate cancer.
Read more →Contact radiotherapy and interstitial brachytherapy for rectal and oesophageal cancers. Includes organ-preserving brachytherapy for rectal cancer and re-irradiation of recurrent disease to avoid surgical resection.
Read more →Multicatheter interstitial brachytherapy allows a second course of radiotherapy to the tumour bed alone after previous breast radiotherapy, making breast conservation a possible alternative to mastectomy in the salvage setting for selected patients. Also offered for accelerated partial breast irradiation and palliative indications.
Read more →Interstitial and surface-mould brachytherapy for skin cancers and soft tissue tumours, including rarer presentations and sites where surgery would be disfiguring or where previous radiotherapy limits further external beam treatment.
Read more →External beam radiotherapy including Intensity-Modulated Radiotherapy (IMRT), Volumetric Modulated Arc Therapy (VMAT), and Stereotactic Ablative Body Radiotherapy (SABR/SBRT) for prostate, spinal metastases, and other indications.
Systemic anti-cancer therapies across gynaecological and urological cancers, including concurrent chemoradiotherapy and standalone systemic treatment. Manages patients on a range of agents from chemotherapy to immunotherapy and targeted therapies.
Dr Abdul-Latif publishes regularly and has presented as first author at multiple ESTRO congresses and other international meetings. His research covers brachytherapy, functional imaging in cervical cancer, systemic therapies, and radiation-related toxicity.
View full publication list on Google ScholarBMJ Oncology — Abdul-Latif M, Conibear J, Thiruthaneeswaran N, Tsang YM
Brachytherapy, Volume 23, Issue 2 — Abdul-Latif M et al. PMID 38383205
Clinical Oncology — Armstrong S, Makris A, Belessiotis-Richards K, Abdul-Latif M et al.
BMJ Open — Abdul-Latif M, Choudhury A, Tharmalingam H et al.
Clinical Oncology — Abdul-Latif M et al. PMID 37246040
Clinical Oncology — Sherriff J, Abdul-Latif M, Tsang YM. PMID 36710152
Cancer Treatment Reviews — Abdul-Latif M et al. PMID 32505807
Clinical Oncology, Volume 31, Issue 2 — Abdul-Latif M et al.
Research Focus
Brachytherapy outcomes across gynaecological, urological, GI and breast cancers. Multiple first-author proffered papers at ESTRO, including salvage brachytherapy and functional MRI.Doctoral Research
Functional MRI of the cervix during chemoradiotherapy — MD(Res) awarded by the University of Manchester under Professor Peter Hoskin, 2025.Pelvic Radiation Disease
Management of radiation-related complications in the acute and chronic phase — an under-recognised area of oncological care that Dr Abdul-Latif is actively researching and improving.Hal Gray Unit · NHS and private practice
Circle Health Group · private practice
Remote appointments UK-wide and international
Fees may vary. Please contact the secretary to confirm before booking.
Video and telephone consultations also available.
Self-pay patients welcome. All major insurers accepted.
Recognised Insurers
Dr Abdul-Latif holds Bupa Platinum status and is Fee Assured — Bupa patients do not incur excess charges on his consultations.
For appointments, referrals, or general enquiries, please contact Dr Abdul-Latif's medical secretary. Self-pay and all major insurers are accepted.
Medical Secretary
Amy Bignell
